Rosen Law Firm Scrutinizes SLM Corporation and Tandem Diabetes Care Over Disclosure Allegations

2025-12-27 companies

New York, Friday, 26 December 2025.
The Rosen Law Firm has issued urgent alerts for investors of SLM Corporation and Tandem Diabetes Care. Amid allegations of concealed loan delinquencies at Sallie Mae and a 19.9% stock plunge at Tandem linked to insulin pump defects, shareholders face a critical window to secure counsel before the February 2026 lead plaintiff deadline.

Allegations of Misleading Financial Disclosures at SLM

The securities class action lawsuit against SLM Corporation specifically targets the timeframe between July 25, 2025, and August 14, 2025, designated as the Class Period [1][3]. The central allegations assert that the company made materially false or misleading statements regarding the stability of its private education loan (PEL) delinquency rates [1][3]. Furthermore, the complaint claims that SLM overstated the effectiveness of its loan modification and loss mitigation programs while simultaneously concealing an increase in early-stage delinquencies [3][4]. These accusations suggest that the company provided a distorted view of its operational health to the market, potentially damaging investor interests when the true financial details were eventually revealed [4].

Critical Timelines for SLM Investors

For investors who purchased SLM securities during the Class Period, the window to actively participate in the litigation as a lead plaintiff is narrowing. The deadline to file a motion with the Court is set for February 17, 2026 [1][3]. It is important to note that no class has been certified at this stage, meaning that unless investors retain their own counsel, they currently remain unrepresented in the proceedings [1]. Participation in any potential future recovery, however, does not necessarily require serving as the lead plaintiff, allowing absent class members to potentially benefit from a settlement [1].

Tandem Diabetes Care: Product Correction Sparks Investigation

In a parallel development, the Rosen Law Firm is investigating potential securities claims involving Tandem Diabetes Care following a sharp decline in the company’s market value earlier this year [2]. On August 7, 2025, Tandem issued a press release announcing a voluntary medical device correction regarding its t:slim X2 Insulin Pumps [2]. The company disclosed a potential speaker-related issue that could cause the device to halt insulin delivery, a critical failure for patients relying on the technology [2]. The market responded immediately to this operational setback, with Tandem’s stock price falling 19.9% on August 7, 2025 [2].

Market Context and Firm Track Record

These legal challenges arrive as SLM Corporation navigates a fluctuating market; as of December 25, 2025, SLM stock closed at $27.52, registering a daily decrease of $0.14 [5]. The Rosen Law Firm, which is soliciting investors for both cases, emphasizes its history of success in similar litigation to establish credibility with potential plaintiffs. The firm was ranked number one by ISS Securities Class Action Services for the number of settlements in 2017 and secured over $438 million for investors in 2019 [1][2]. Investors impacted by the alleged disclosures at SLM or the product correction at Tandem are encouraged to review their transaction history against the specified dates to assess their eligibility for recourse [1][2].

Sources

Securities Litigation Class Action